Translating these findings, a transcriptome-based drug repurposing screen identified 5 chemical candidates, 4 of which are potent cyclin-dependent kinase inhibitors, aligning with the frequent loss-of-function mutations in <i>TP53</i> and <i>CDKN2A</i> observed in ESCC. This evidence concerns the gene TP53 and esophageal squamous cell carcinoma.